Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MVC-COV1901,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Published In The Lancet Respiratory Medicine
Details : The results from study served as basis for immunobriding that gives MVC-COV1901 vaccine's Emergency Use Authorization in Taiwan and can support the advancement in subsequent developments.MVC-COV1901 vaccine involves molecular modifications to S-2P pre-fu...
Product Name : MVC-COV1901
Product Type : Vaccine
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : MVC-COV1901,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MVC-COV1901,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Dynavax Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First participant has been dosed in the Phase 2 clinical trial evaluating MVC’s COVID-19 vaccine candidate, MVC-COV1901. MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax.
Product Name : MVC-COV1901
Product Type : Vaccine
Upfront Cash : Inapplicable
January 25, 2021
Lead Product(s) : MVC-COV1901,Aluminium Hydroxide,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Dynavax Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : S-2P Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Dynavax Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The first participant in MVC's Phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 13, 2020
Lead Product(s) : S-2P Vaccine,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Dynavax Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine, Adjuvanted,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Dynavax Technologies
Deal Size : Undisclosed
Deal Type : Partnership
Dynavax and Medigen Partner to Develop Adjuvanted Covid-19 Vaccine
Details : The partners will leverage Medigen’s stable prefusion form of the SARS-CoV2 recombinant spike protein in combination with Dynavax’s advanced adjuvant CpG 1018.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 23, 2020
Lead Product(s) : COVID-19 Vaccine, Adjuvanted,CPG ODN 1018
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Dynavax Technologies
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration
Taiwan firm teams up with US to develop Covid-19 vaccine
Details : Medigen signed an agreement with the NIH allowing it to obtain the candidate vaccine virus for potential use in humans to jump-start candidate vaccine development for Covid-19 in Taiwan.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 17, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Collaboration